Ryota Tamura

Research field (1)： Other

Research theme for competitive and other funds (2)：

2022 - 2025 Hypoxic micro-environment and therapeutic advances for NF2 schwannomas
2016 - 2017 iPS細胞を用いた悪性グリオーマに対する遺伝子細胞治療の基礎的研究

Papers (56)：

Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. 41. 2. 61-72
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranai, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2023
Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, et al. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. Brain Tumor Pathology. 2023
Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, et al. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. Brain Tumor Pathology. 2023

ｍore...

MISC (8)：

Ezaki T, Tanaka T, Tamura R, Yamamoto Y, Takei J, Morimoto Y, Imai R, Kuranari Y, Akasaki Y, Murayama Y, et al. ANGI-1 Regulation of alternative angiogenic factors in bevacizumab therapy for glioblastoma. Neuro-Oncology Advances. 2023. 5. 5. v1-v2
Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Tohmoto K, K, Kuranari Y, Imai R, Yamamoto Y, et al. A prospective multicenter phase I/IIa study of prospective neoadjuvant bevacizumab for newly diagnosed glioblastoma. Neuro-Oncology Advances. 2022. 4. 3. iii7
Tanaka T, Takei J, Teshigawara A, Tohmoto K, Yamamoto Y, Hasegawa Y, Tamura R, Sasaki H, Akasaki Y, Murayama Y. Impact of neoadjuvant bevacizumab on transcriptional factor for stemness, macrophage polarization, and oxygenation of tumor microenvironment in glioblastoma. Neuro-Oncology Advances. 2021. 3. 6. vi1
Ryota Tamura, Mizuto Sato, Yukina Morimoto, Kentaro Ohara, Kenzo Kosugi, Yumiko Oishi, Yuki Kuranari, Makoto Murase, Kazunari Yoshida, Masahiro Toda. Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors. Experimental and molecular pathology. 2020. 114. 104408-104408
Tanaka T, Tamura R, Yamamoto Y, Morimoto Y, Teshigawara A, Tochigi S, Hasegawa Y, Takei J, Sasaki H, Murayama Y. Alteration in immune regulatory cels before and after treatment by Stupp regimen with or without bevacizumab for glioblastoma. Neuro-Oncology Advances. 2019. 1. 2. ii4-iii5

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page